Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

Infliximab 6etrolizumab 5Adalimumab 4golimumab 3Nivolumab 3CT-P13 3Specimen Handling 2Educational Status 2Colonoscopy 2vedolizumab 1pembrolizumab 1peficitinib 1cabozantinib 1Vitamin E 1Sutures 1Surgical Instruments 1Standard of Care 1Ringer's Lactate 1Proctocolectomy, Restorative 1Proctectomy 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Platinum Compounds 1Papillomavirus Vaccines 1Narrow Band Imaging 1NX-13 1Methylprednisolone 1Methods 1Mesalamine 1Medical Marijuana 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colitis, Ulcerative × NX-13 × Clear all
NCT05785715 2025-07-01

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

AbbVie

Phase 2 Terminated
81 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡